Skip to main content

Exact Sciences Corporation (EXAS)

NASDAQ: EXAS · IEX Real-Time Price · USD
98.28
+0.06 (0.06%)
After-hours:Sep 23, 2021 7:58 PM EDT
98.22
-4.03 (-3.94%)
At close: Sep 23, 4:00 PM
Market Cap17.58B
Revenue (ttm)1.71B
Net Income (ttm)-864.77M
Shares Out171.49M
EPS (ttm)-5.27
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,134,863
Open103.00
Previous Close102.25
Day's Range97.79 - 103.27
52-Week Range71.86 - 159.54
Beta1.29
AnalystsStrong Buy
Price Target148.88 (+51.6%)
Est. Earnings DateOct 26, 2021

About EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX ...

IndustryBiotechnology
Founded1995
CEOKevin Conroy
Employees4,800
Stock ExchangeNASDAQ
Ticker SymbolEXAS
Full Company Profile

Financial Performance

In 2020, Exact Sciences's revenue was $1.49 billion, an increase of 70.19% compared to the previous year's $876.29 million. Losses were -$848.53 million, 910.2% more than in 2019.

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for Exact Sciences stock is "Strong Buy." The 12-month stock price forecast is 148.88, which is an increase of 51.58% from the latest price.

Price Target
$148.88
(51.58% upside)
Analyst Consensus: Strong Buy

News

The 1 Stock I'd Buy Right Now

The pandemic isn't over yet.

Other symbols:FLGTGHILMN
5 days ago - The Motley Fool

3 Crash-Ready Stocks to Buy in September

History says this month can be scary. These stocks can get you through it.

Other symbols:PFEVRTX
1 week ago - The Motley Fool

This Cancer Screening Company Has A Better 5-Year Return Than Pfizer, Johnson & Johnson And Gilead

Small-cap stocks have a history of outperforming large-cap names as they have the potential for rapid growth and have event-driven moves for share prices. A company focused on cancer screening and diagn...

2 weeks ago - Benzinga

Exact Sciences to participate in September investor conferences

MADISON, Wis. , Sept. 1, 2021  /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to ...

3 weeks ago - PRNewsWire

Why Is Exact Sciences (EXAS) Down 9.4% Since Last Earnings Report?

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?

3 weeks ago - Zacks Investment Research

3 Top Healthcare Stocks to Buy for August

With excellent prospects, these three companies are built to last and today's prices are attractive.

Other symbols:BMYMDT
1 month ago - The Motley Fool

Exact Sciences receives regulatory approval for the Oncotype DX Breast Recurrence Score® Program in Japan

MADISON, Wis., Aug. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the Oncotype DX Breast Recurrence ...

1 month ago - PRNewsWire

Clinical Gastroenterology and Hepatology Publishes Data Showing Exact Sciences' Oncoguard™ Liver Liquid Biopsy Test D...

MADISON, Wis., Aug. 13, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced today that the performance of its Oncoguard™ Liver liquid biopsy test is now published online in the peer-revie...

1 month ago - PRNewsWire

10 Stocks to Buy From Cathie Wood's Fleet of ETFs

The haters have come out against portfolio manager Cathie Wood. In fact, an ETF is preparing to launch that bets against her stocks to buy.

1 month ago - InvestorPlace

Exact Sciences (EXAS) Q2 Loss Wider Than Expected, Revenues Top

Exact Sciences' (EXAS) legacy Screening business sees significant improvement in revenues during the second quarter on Cologuard volume growth.

1 month ago - Zacks Investment Research

Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates

Exact Sciences (EXAS) delivered earnings and revenue surprises of -43.06% and 3.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Exact Sciences: Q2 Earnings Insights

Shares of Exact Sciences (NASDAQ:EXAS) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 77.59% over the past year to ($1.03), whi...

1 month ago - Benzinga

Exact Sciences Announces Second Quarter 2021 Results

MADISON, Wis., July 28, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $434.8 million for the second quarter ended June 30, 2021, compared...

1 month ago - PRNewsWire

Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Should You Buy?

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Bull of the Day: Exact Sciences (EXAS)

EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year

2 months ago - Zacks Investment Research

Where Will ARK Genomic Revolution ETF Be in 5 Years?

Cathie Wood's genomics ETF is making big bets on the "Genomic Age."

Other symbols:ARKGNTLANVTAPACB
2 months ago - The Motley Fool

Exact Sciences schedules second quarter 2021 earnings call

MADISON, Wis., July 8, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its second quarter 2021 financial results after the close of the U.S. fi...

2 months ago - PRNewsWire

Strong Revenue Trend Could Drive EXACT Sciences Corporation Stock To $160

Up around 2.5x from its low in March 2020, at the current price of $126 per share, we believe EXACT Sciences Corporation stock has further upside potential. EXAS, a molecular diagnostics company, has se...

3 months ago - Forbes

Tuesday Analyst Upgrades and Downgrades: Campbell Soup, Exact Sciences, Exelixis, Spirit Airlines, Sarepta, ZTO and More

Tuesday's futures were fairly positive after a somewhat mixed start to the week.

Other symbols:CPBEXELSAVESRPTZTO
3 months ago - 24/7 Wall Street

Exact Sciences (EXAS) Down 1.4% Since Last Earnings Report: Can It Rebound?

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

Here's Why You Should Hold on to Exact Sciences (EXAS) Stock

Investors are optimistic about Exact Sciences (EXAS) on solid first-quarter performance and strategic partnerships.

3 months ago - Zacks Investment Research

Exact Sciences (EXAS) Reveals Promising Data on Cologuard

Modeling data exhibits efficacy of Exact Sciences' (EXAS) Cologuard compared to FIT and other colorectal cancer diagnostic options.

3 months ago - Zacks Investment Research

4 Unstoppable Healthcare Stocks to Buy on the Dip

They're well below peak levels set earlier this year. But they could be huge winners over the long run.

Other symbols:CRSPTDOCTWST
3 months ago - The Motley Fool

Boston Scientific, Gap, Molson Coors and More Tuesday Afternoon Analyst Calls

With the trading day more than halfway over, the markets had dipped after a relatively strong start to the day.

3 months ago - 24/7 Wall Street

Exact Sciences to participate in June investor conferences

MADISON, Wis., May 24, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to par...

3 months ago - PRNewsWire